Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Categories (click each to see list of all clinical trials associated with that category): Bone Marrow Transplant (BMT)/Graft Versus Host Disease (GVHD)
Current Status: Open to accrual
Phase: N/A
Principal Investigator: Al-Kadhimi, Zaid
Contact Information:
Penny Hardiman, RN
402-559-4135
penny.hardiman@unmc.edu
Eligibility: https://clinicaltrials.gov/ct2/show/study/NCT03904134?term=NCT03904134&draw=2&rank=1#eligibility
Summary
Primary Objective:
1. Compare overall survival between Very Likely to find a matched unrelated donor search
prognosis patients and Very Unlikely to find a matched unrelated donor search prognosis
patients who are evaluable.
Secondary Objectives:
1. To estimate and compare the cumulative incidence of receiving a transplant according to donor search prognosis
2. To describe barriers to achieving transplantation with different donor search strategies
Post-Transplant Objectives:
3. To compare overall survival, relapse, disease-free survival, treatment-related mortality,
and acute and chronic GVHD in patients transplanted for malignant diseases, according to
the donor search prognosis and the alternative donor used.
4. To describe survival and acute and chronic GVHD in patients with acquired aplastic
anemia and sickle cell disease after transplantation, according to the donor search prognosis and the alternative donor used.
5. In patients with AML or ALL in first complete remission or early stage MDS (refractory
anemia, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage
dysplasia, 5q- syndrome or <5% bone marrow blasts) treated with a limited subset of
conditioning and GVHD prophylaxis regimens and transplanted with either matched
unrelated donors or haploidentical related donors (QOL Substudy), to compare QOL and
describe primary graft failure, cGVHD, time until off systemic immunosuppression,
aGVHD grade III-IV and cGVHD requiring immunosuppression-free, relapse-free
survival (GRFS), moderate-severe cGVHD relapse-free survival (CRFS), current CRFS
(still on systemic treatment for cGVHD), hospital days in the first 100 post-transplant days,
infections, immune reconstitution and late effects after transplantation, according to the
donor search prognosis and alternative donor used.